Nesidioblastosis–Nonlocalized Hyperinsulinemic Hypoglycemia: A Diagnosis Likely Missed

Parul Gupta1, Vivek Agarwal2, Deepak Khandelwal3, Monika Garg4, Deep Dutta5, Aakash Garg6

ABSTRACT
Endogenous hyperinsulinemic hypoglycemia (EHH) on investigation shows low blood glucose because of excessive endogenous insulin production. The most common cause of EHH is insulinoma, an islet cell tumor, the incidence of which is approximately 4 per one million patients per year.1 The term nesidioblastosis was introduced by Laidlaw in 1938, for the diffuse proliferation of pancreatic islet cells which were budding from ductal epithelium.2 It is usually identified in infants but is uncommon in adults.3 Noninsulinoma pancreatogenous hypoglycemic (NIPH) syndrome now incorporates adult onset nesidioblastosis,3 which is an uncommon disease, representing about 0.5–5% cases of EHH.4 In adult nesidioblastosis, there is a functional dysregulation of beta cells, the cause of which is unknown.5 It is difficult to distinguish between nesidioblastosis and insulinoma, both clinically and biochemically. Histopathology evaluation clinches the final diagnosis. We herein present a rare case of symptomatic adult onset EHH, the cause for which could not be localized on imaging. Distal pancreatectomy led to clinical improvement with histopathology confirming nesidioblastosis.

Keywords: Hypoglycemia, Insulinoma, Islet cell hyperplasia, Nesidioblastosis, Pancreatectomy.

Introduction
Endogenous hyperinsulinemic hypoglycemia (EHH) on investigation shows low blood glucose and normal to high blood insulin/C-peptide levels due to excessive endogenous insulin production. The most common cause of EHH is insulinoma, an islet cell tumor, the incidence of which is approximately 4 per one million patients per year.1 The term nesidioblastosis was introduced by Laidlaw in 1938, for the diffuse proliferation of pancreatic islet cells which were budding from ductal epithelium.2 It is usually identified in infants but is uncommon in adults.3 Noninsulinoma pancreatogenous hypoglycemic (NIPH) syndrome now incorporates adult onset nesidioblastosis,3 which is an uncommon disease, representing about 0.5–5% cases of EHH.4 In adult nesidioblastosis, there is a functional dysregulation of beta cells, the cause of which is unknown.5 It is difficult to distinguish between nesidioblastosis and insulinoma, both clinically and biochemically. Histopathology evaluation clinches the final diagnosis. We herein present a rare case of symptomatic adult onset EHH, the cause for which could not be localized on imaging. Distal pancreatectomy led to clinical improvement with histopathology confirming nesidioblastosis.

Case Description
A Forty-five-year-old male patient was admitted in emergency department of our hospital with a sudden loss of consciousness along with preceding symptoms of uneasiness and sweating. His blood glucose was 30 mg/dL. The patient regained consciousness after giving intravenous glucose with normalization of blood glucose. As per history given by family members, the patient had been experiencing similar episodes for the past 12 years. The initial episodes used to be mild and were relieved with oral glucose intake. To start, these episodes were primarily in early morning after 6–8 hours of fasting; however, in past 6 months episodes could occur any time of the day, with progressive increase in severity. Also, the patient had multiple episodes of loss of consciousness in the last few weeks, suggestive of more severe episodes. Patient also complained of significant weight gain of 10 kg over the last 4 years. There was no history of alcohol intake or intestinal surgery. There was no history of systemic illness or prolonged drug intake. General physical and systemic examination was within normal limits.

Several episodes of severe hypoglycemia (blood glucose <50 mg/dL) were documented in the first few days of hospital admission. During one of the hypoglycemic episodes in hospital (laboratory blood glucose 25 mg/dL), investigations revealed elevated serum insulin (56.65 μIU/mL; hyperinsulinemia) and increased C-peptide levels (10.25 ng/mL). Subsequent thyroid function test and serum cortisol evaluation were within normal limits (Table 1). Multiple imaging studies like contrast-enhanced magnetic resonance imaging (MRI) abdomen, contrast-enhanced...
Nesidioblastosis–Nonlocalized Hyperinsulinemic Hypoglycemia

**Table 1: Laboratory investigations in our patient**

| Test                          | Patient value | Laboratory reference range |
|-------------------------------|---------------|---------------------------|
| Serum cortisol (7 am–9 am)    | 8.4 μg/dL     | 4.2–38.4 μg/dL            |
| Serum TSH*                    | 2.59 μIU/mL   | 0.4–5.5 μIU/mL            |
| Serum total T3                | 1.84 nmol/L   | 0.9–2.8 nmol/L            |
| Serum total T4                | 87.53 nmol/L  | 58–161 nmol/L             |
| Serum insulin antibodies      | 2.3 U/mL      | Negative ≤15 U/mL         |
| Serum IGF-1**                 | 147 ng/mL     | 69–224 ng/mL              |

*Thyroid stimulating hormone
**Insulin-like growth factor-1

**Discussion**

The patients of EHH clinically present with Whipple’s triad, consisting of hypoglycemic symptoms, documented hypoglycemia (blood glucose levels <50 mg/dL), and correction of hypoglycemia leading to immediate relief of symptoms.⁸

Hypoglycemia is responsible for clinical manifestations of EHH,⁹ and hypoglycemic symptoms are grouped in two major categories, adrenergic or neuroglycopenic. Adrenergic symptoms, such as diaphoresis, weakness, nausea, tremor, anxiety, warm sensations, and palpitations, are because of release of catecholamines.² Loss of consciousness, diplopia, blurred vision, confusion, abnormal behavior, and amnesia are the neuroglycopenic symptoms. Endogenous hyperinsulinemia (serum insulin ≥3 μIU/mL and serum C-peptide ≥0.6 ng/mL) in the presence of concomitant hypoglycemia (blood glucose ≤50 mg/dL) clinches diagnosis of EHH, regardless of whether hypoglycemic symptoms occur in the fasting or postprandial state or after exercise.⁹
Our patient also experienced severe neuroglycopenic symptoms at any time of the day with loss of consciousness with documented plasma glucose levels as low as 25 mg/dL during the episodes. Also, the plasma insulin levels and also C-peptide levels were high during these hypoglycemic episodes. Henceforth, a diagnosis of EHH was made in our patient. Multiple imaging studies including endoscopic ultrasound and contrast CT angiography abdomen as well as intraoperative imaging studies failed to localize any tumor in the pancreas.

Histopathology of thin sections showed normal exocrine component made up of lobular units of acini and ducts and endocrine component made up of islets of Langerhans. The islets were increased in number and average diameter (Fig. 3). There are no universally agreed upon diagnostic criteria of pancreatic islet cell hyperplasia. Rindi and Solcia defines pancreatic islet cell hyperplasia as an expansion of the endocrine cell mass to more than 2% (in adults) or 10% (in infants) of the total pancreatic mass. As the detailed pancreatic morphometry in a clinical specimen is difficult, so there is subjectivity in the diagnosis of pancreatic islet cell hyperplasia. An increase in islet numbers and an islet size larger than 250 μm in diameter are taken as evidence of pancreatic islet cell hyperplasia in most previous studies. The average diameter of islets in our case was also more than 250 μm. Therefore, histopathology clinched the final diagnosis of hyperplasia of Langerhans islets or nesidioblastosis.

Another cause of EHH is insulin autoimmune syndrome which shows presence of autoantibodies to native insulin or the insulin receptor. Insulin autoimmune syndrome is also uncommon, and only scattered cases have been reported worldwide. In our patient, the insulin antibodies were very low (Table 1).

Noninsulinoma pancreaticotogenous hypoglycemic syndrome now includes adult onset nesidioblastosis. The association between bariatric surgery and NIPH is controversial. Hypoglycemia after bariatric surgery occurs commonly and is mostly due to dumping syndrome, however, in a minority of patients hypoglycemia can only be controlled by partial pancreatectomy.

**Conclusion**

In adult patients with EHH with negative imaging, adult onset islet cell hyperplasia (nesidioblastosis) should always be suspected. Concomitant testing for plasma insulin and C-peptide levels during the hypoglycemic episodes clinches the diagnosis of EHH. Symptomatic cases can be successfully treated by distal pancreatectomy with subsequent histopathology giving the final diagnosis.

**References**

1. Service FJ. Diagnostic approach to adults with hypoglycemic disorders. Endocr Rev 1999;20(1):51–59. DOI: 10.1210/edrv-20-1-51.
2. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005;19:783–798. DOI: 10.1016/j.bpg.2005.05.008.
3. Jabri AL, Bayard C. Nesidioblastosis associated with hyperinsulinemic hypoglycemia in adults: review of the literature. Eur J Intern Med 2004 Nov;15(7):407–410. DOI: 10.1016/j.ejim.2004.06.012.
4. Anlauf M, Wieben D, Perren A, et al. Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of beta-cell changes. Am J Surg Pathol 2005;29(4):524–533. DOI: 10.1097/01.pas.0000151617.14598.ae.
5. Service FJ, Natt N, Thompson GB, et al. Noninsulinomapancreaticotogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. J Clin Endocrinol Metab 1999;84(5):1582–1589. DOI: 10.1210/jc.84.5.1582.
6. Ramirez-González LR, Sotelo-Álvarez JA, Rojas-Rubio P, et al. Nesidioblastosis in the adult: a case report. Cir Cir 2015;83(4):324–328. DOI: 10.1016/j.circen.2015.09.006.
7. Dravecka I, Lazurova I. Nesidioblastosis in adults. Neoplasma 2014;61(3):252–256. DOI: 10.14199/ne_2014_047.
8. Field JB. Insulinoma. In: Mazzaferrri EL, Samaan NA. Endocrine tumours. Boston: Blackwell Scientific publications; 1993. pp. 497–530.
9. De Santibañes M, Cristiano A, Mazza O, et al. Endogenous hyperinsulinemic hypoglycemia syndrome: surgical treatment. Cir Esp 2014;92(8):547–552. DOI: 10.1016/j.ciresp.2013.04.025.
10. Rindi G, Solcia E. Endocrine hyperplasia and dysplasia in the pathogenesis of gastrointestinal and pancreatic endocrine tumors. Gastroenterol Clin North Am 2007;36(4):851–865. DOI: 10.1016/j.gtc.2007.08.006.
11. Weidenheim KM, Hinchey WW, Campbell WGR. Hyperinsulinemic hypoglycemia in adults with islet-cell hyperplasia and degranulation of exocrine cells of the pancreas. Am J Clin Pathol 1983;79(1):14–24. DOI: 10.1093/ajcp/79.1.14.
12. Starke A, Saddig C, Kirch B, et al. Islet hyperplasia in adults: challenge to preoperatively diagnose non-insulinoma pancreatogenic hypoglycemia syndrome. World J Surg 2006;30(5):670–679. DOI: 10.1007/s00268-005-0543-6.
13. Lupsa BC, Chong AV, Cochran EK, et al. Autoimmune forms of hypoglycemia. Medicine (Baltimore) 2009;88(3):141–153. DOI: 10.1097/MD.0b013e3181a5b42e.
14. Uchigata Y, Hirata Y, Iwamoto Y. Insulin autoimmune syndrome (hirata disease): epidemiology in Asia, including japan. Diabetol Int 2010;1:21–25. DOI: 10.1007/s13334-010-0001-z.
15. Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005;353(3):249–254. DOI: 10.1056/NEJMoa043690.